Objective:
Report two-year efficacy, supplemental injection requirements, and safety-management details for intravitreal 4D-150 gene therapy in neovascular AMD.
Approach:
- Study: Interview discussion of updated two-year data from the phase 1/2 PRISM program.
- Treatment groups: Results were described for recalcitrant patients and more recently diagnosed patients.
Key Findings:
- The speaker reported stable central subfield thickness and best-corrected visual acuity over two years.
- Among recalcitrant patients, 22% received no supplemental injections and nearly 59% received two or fewer over two years.
- Among more recently diagnosed patients, 66% received no supplemental injections and nearly 90% received two or fewer over two years.
- The speaker said the trial uses 20 weeks of topical steroids to address inflammation, followed by tapering.
Interpretation:
The interview describes reduced supplemental injection requirements over two years, including among patients characterized as difficult to treat. The speaker cautioned that some patients may still require additional treatment.
Limitations:
- The context does not provide sample sizes, detailed methods, statistical analyses, or full safety results.
- Findings are reported through an interview summary rather than a complete study report.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
